OVERVIEW

Updates in Genomic Testing for Breast Cancer: Rapid Response From Chicago is organized by Vindico Medical Education.

Release Date: 6/11/2019
Expiration Date: 6/10/2020

Target Audience:
The intended audience for the activity is oncologists, hematologist-oncologists, pathologists, and other health care professionals involved in the treatment of patients with early-stage breast cancer.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Description:
Multigene assays that evaluate an array of prognostic and/or predictive molecular markers have become critical for the optimal management of patients with breast cancer. Although many of these assays can be utilized for prognostication, only some can be used to predict response to therapy, which can be helpful in evaluating patients who have been receiving treatment for several years. For patients with HR+ early-stage breast cancer, assays that can predict response to endocrine therapy may be useful. As the prognostic and/or predictive value of these assays continue to be evaluated for patients with HR+ breast cancer, it is essential that health care professionals have access to these findings. Within this CME activity, experts in the field will differentiate multigene assays for patients with HR+/HER2- breast cancer based on both prognostic and predictive value. They also will review the latest clinical evidence regarding these assays, which can be used to predict response to extended endocrine therapy for patients with HR+/HER2- breast cancer.

Learning Objectives:
Upon successful completion of this activity, participants should be able to:
• Differentiate available multigene tests for patients with HR+/HER2- breast cancer based on both prognostic and predictive value.
• Assess the latest clinical evidence regarding genomic tests that can be used to predict response to extended endocrine therapy for patients with HR+/HER2- breast cancer.